Office of the Director - May 26, 2011
The NHLBI has stopped AIM-HIGH, a clinical trial studying a blood lipid treatment, 18 months earlier than planned. The trial found that adding high-dose, extended-release niacin to statin treatment in people with heart and vascular disease did not reduce the risk of cardiovascular events, including heart attacks and stroke. Read the full press release and related materials.
Dr. Shurin discusses the early termination of the trial in the brief video below.